268 related articles for article (PubMed ID: 10470196)
1. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
Sütterlin M; Bussen S; Trott S; Caffier H
Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
[TBL] [Abstract][Full Text] [Related]
4. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
6. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
7. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
[TBL] [Abstract][Full Text] [Related]
8. The serum tumor marker M3/M21 in the follow-up of breast cancer patients.
Tempfer C; Hanzal E; Zeillinger R; Koelbl H; Dadak C; Kainz C
Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765
[TBL] [Abstract][Full Text] [Related]
9. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
10. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
[TBL] [Abstract][Full Text] [Related]
12. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer.
Lumachi F; Basso SM; Bonamini M; Marzano B; Milan E; Waclaw BU; Chiara GB
Anticancer Res; 2010 Jun; 30(6):2331-4. PubMed ID: 20651388
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
[TBL] [Abstract][Full Text] [Related]
14. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
15. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
16. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of four serological tumor markers for the detection of breast cancer.
Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
[TBL] [Abstract][Full Text] [Related]
19. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]